Phage Therapeutics
Developing bacteriophage-based therapies engineered for targeted activity against multidrug-resistant bacterial infections.
Biotechnology
Advancing targeted therapies for antimicrobial resistance
PALDARA develops next-generation bacteriophage therapeutics and advanced biomaterial delivery platforms designed to prevent and treat multidrug-resistant infections with precision.
Clinical collaboration
Working with Mayo Clinic toward first human trials
PALDARA and Mayo Clinic are advancing a delivery platform that stabilizes and sustains bacteriophages, aiming to make phage therapy practical for patients.
Clinical Research News, September 23, 2025As covered by
- The Journal Record
- Scientist Live
- Clinical Research News
- Bio-IT World
- BioProcess International
- KFOR
- FOX23
- NewsBreak
Partner with us
Three ways to work with PALDARA
Investors
Back a low-cost, shelf-stable platform heading toward first human trials with Mayo Clinic.
Talk investmentClinical partners
Bring phage therapy to patients with drug-resistant infections who have run out of options.
Discuss a partnershipResearch collaborators
Work with us on phage discovery, hydrogel formulation and preclinical studies.
Propose a collaborationMission
Engineering precision antibacterial platforms
Paldara Pharmaceuticals is focused on translating bacteriophage science into clinically relevant therapies that address the growing global burden of antimicrobial resistance.
Our proprietary phage-hydrogel approach is designed to deliver highly targeted antibacterial activity while reducing dependence on conventional antibiotics and supporting better therapeutic outcomes.
Focus Areas
Built for scientific progress
Why It Matters
Responding to a global resistance challenge
AMR demands new therapeutic strategies. PALDARA is building targeted antibacterial solutions that combine biological specificity with advanced delivery science to support the future of infection care.
Room temp
Shelf-stable hydrogel keeps phages viable without refrigeration
3 routes
Rehydrated for injection, ingestion, or topical application
~$8
Projected cost per unit, vs. hundreds or thousands for last-line antibiotics
“At the Mayo Clinic, we have now treated nearly 20 patients with phage or phage-adjacent therapies under FDA Expanded Access. Each case underscores both the urgency of the antimicrobial resistance crisis and the hope offered by innovations like Paldara's platform.”
Dr. Gina Suh
Director, Mayo Clinic Phage Therapy Program
Via The Journal RecordPartner with PALDARA
Connect with our team to discuss research collaboration, scientific inquiries, or partnership opportunities in next-generation anti-infective development.